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Background: Peri-operative statin therapy in cardiac surgery cases is reported to reduce the rate of mortality,
stroke, postoperative atrial fibrillation, and systemic inflammation. Systemic inflammation could affect the
hemodynamic parameters and stability. We set out to study the effect of statin therapy on perioperative
hemodynamic parameters and its clinical outcome.
Methods: In a single center study from 2006 to 2007, peri-operative hemodynamic parameters of 478 patients, who
underwent cardiac surgery with cardiopulmonary bypass, were measured. Patients were divided into those who
received perioperative statin therapy (n = 276; statin group) and those who did not receive statin therapy (n = 202;
no-statin group). The two groups were compared together using Kolmogorov-Smirnov-Test, Fisher’s-Exact-Test, and
Student’s-T-test. A p value< 0.05 was considered as significant.
Results: There was no significant difference in the preoperative risk factors. Onset of postoperative atrial fibrillation
was not affected by statin therapy. Extended hemodynamic measurements revealed no significant difference
between the two groups, apart from Systemic Vascular Resistance Index (SVRI) . The no-statin group had a
significantly higher SVRI (882 ± 206 vs. 1050 ± 501 dyn s/cm5/m2, p = 0.022). Inotropic support was the same in both
groups and no significant difference in the mortality rate was noticed. Also, hemodynamic parameters were not
affected by different types and doses of statins.
Conclusions: Perioperative statin therapy for patients undergoing on-pump coronary bypass grafting or valvular
surgery, does not affect the hemodynamic parameters and its clinical outcome.
Keywords: Cardiac surgery, Statin therapy, Hemodynamic, OutcomeBackground
Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-co-
enzyme A (HMG CoA) reductase. They are an established
treatment for hypercholesterolemia by lowering plasma
levels of low-density lipid cholesterol (LDL-C) [1,2]. LDL-C
plays an important role in the pathogenesis of atheroscler-
osis [3]. Consequently statins are used effectively in primary
and secondary prevention of cardiovascular diseases,
like coronary heart disease, myocardial infarction or stroke* Correspondence: Popov@med.uni-goettingen.de
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reproduction in any medium, provided the or[4-7]. Apart from their lipid lowering effects, some authors
state that patients undergoing cardiac surgery with pul-
monary bypass would benefit from intensified perioperative
statin therapy. It can reduce the rate of artrial fibrillation,
mortality and systemic inflammation [8,9].
Several studies have already demonstrated the pleiotropic
effect of the statins. Based on meta-analysis of over 30 000
patients, Liakopoulos et al. confirmed the clinical benefit of
preoperative statin therapy in early postoperative outcomes
for cardiac surgery patients [10]. They showed a 4.3% abso-
lute risk reduction in artrial fibrillation and a 1.5% absolute
risk reduction for early all-cause mortality [10].
Systemic inflammation is a potential complication of
cardiopulmonary bypass after cardiac operations [11,12].
Artificial material of extracorporeal circuit induces the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical and demographic characteristics of the
study population
Statin No Statin p-value
(n = 276) (n = 202)
Age and gender
Age (years) 68 ± 8.9 68 ± 10.9 0.94
Male / Female (%) 69.2/30.8 59.9/40.1 0.03
Risk factors
Body mass index (kg/m²) 28 ± 4.7 27.1 ± 4.4 0.03
Smokers (%) 39.9 27.7 0.006
Hypertension (%) 77.5 68.8 0.03
Diabetes mellitus (%) 37 23.3 0.001
Positive family history (%) 13.4 4 0.11
Ejection fraction (EF; %) 54 ± 14 53 ± 14 0.75
Peripheral disease (%) 8.3 5 0.15
Neurocerebral events (%) 12.3 12.4 0.98
Pulmonary hypertension (%) 5.8 11.9 0.02
COPD (%) 9.1 6.4 0.30
Dialysis (%) 0.4 1 0.39
Renal dysfunction (%) 14.5 13.4 0.73
Renal function variables
Serum creatinine (mg/dl) 1.17 ± 0.75 1.18 ± 0.74 0.82
Urea (mg/dl) 22 ± 13 22 ± 13 0.54
Estimated creatinine clearance
(ml/min)
75 ± 32 77 ± 34 0.68
Hematocrit (%) 40 ± 6 39 ± 6 0.31
Preoperative medications
ß-blockers (%) 67 61.4 0.20
ACE inhibitors (%) 60.5 45 0.0008
Oral nitrates (%) 22.5 13.9 0.02
Antiarrhythmics (%) 4 3.5 0.76
Diuretics (%) 40 43.1 0.48
Antidiabetics (%) 21.7 14.9 0.06
Further antihypertensives (%) 25.4 18.3 0.07
Bronchodilator (%) 3.3 3 0.86
Anticoagulation (%) 76.8 59.4 0.0001
Associated surgical procedures
CABG (n = 252 / 52.7%) (%) 68.1 31.7 <0.0001
Valve (n = 107 / 22.4%) (%) 10.9 38.1 <0.0001
Combined procedures
(n = 101 / 21.1%) (%)
20.3 22.3 0.65
Other procedures (n = 18 / 3.8%) (%) 0.7 7.9 <0.0001
Euroscore additive 5 ± 4 6 ± 4 0.29
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systemic inflammatory response syndrome (SIRS) [13].
The surgical trauma could also induce systemic inflam-
mation. Important pro-inflammatory cytokines are
mainly Interleukin-6 (IL-6), Interleukin-8 (IL-8) and
Tumor necrosis factor-alpha (TNF-α) [14]. Youssef et al.
have already shown in mice model, that statins suppress
inflammatory reactions in autoimmune diseases [15].
There are clinical studies showing a post-operative
decrease of pro-inflammatory cytokines in patients with
cardiopulmonary bypass [16,17].
Perioperative statin therapy can influence the post-
operative outcome of patients with cardiopulmonary
bypass. Meanwhile the effect of statins on peri-operative
hemodynamic parameters has not been studied in detail
yet. Systemic inflammation induces the release of pro-
inflammatory cytokines and the resultant systemic vaso-
dilatation. As a result peripheral resistance decreases and
there should be measureable change in hemodynamic
parameters. This state is commonly known as hyperdy-
namic circulation [18]. In view of the fact that statins
may have an anti-inflammatory effect, they could poten-
tially improve the postoperative hemodynamics and
clinical outcome. The aim of this study was to detect the
anti-inflammatory effects of statins by referencing it to
the hemodynamic parameters in cardiac surgery patients
with cardiopulmonary bypass.
Methods
The retrospective single centre study was approved by
the ethics committee of the Medical Faculty, University
of Göttingen, Germany. The study groups were already
part of a former prospective study. Individual patient
consent was obtained before enrolling in the study. From
December 2006 to December 2007, we included 478
patients (312 males and 166 females), who underwent
cardiac surgery with cardiopulmonary bypass.
The study population was divided into two groups.
One group (276 patients) received perioperative statins
and the other group (202 patients) did not.
Demographic and clinical data
The following demographic and clinical data were
collected preoperatively: age, gender, risk factors (body
mass index, smoking, hypertension, diabetes mellitus,
positive family history, ejection fraction, peripheral arter-
ial disease, neurocerebral events, pulmonary hyperten-
sion, chronic obstructive pulmonary disease (COPD),
dialysis and renal dysfunction), renal function variables
(serum creatinine, serum urea, estimated creatinine
clearance and hematocrit), preoperative medications (ß-
blockers, ACE inhibitors, oral nitrates, antiarrhythmics,
diuretics, antidiabetics, further antihypertensive agents,
bronchodilators and anticoagulation), urgency of surgery,associated surgical procedures (coronary artery bypass
grafting, valve, combined procedures and others) and the
Euroscore [19]. The clinical and demographic character-
istics are summarized in Table 1.
Table 2 Statin dosages of the statin group
n (%)
Simvastatin
10 mg 18 (11)
15 mg 4 (2)
20 mg 64 (39)
25 mg 1 (1)
40 mg 77 (46)
Atorvastatin
10 mg 6 (15)
20 mg 23 (59)
40 mg 8 (21)
80 mg 2 (5)
Fluvastatin
40 mg 5 (21)
80 mg 16 (79)
Pravastatin
5 mg 2 (4)
10 mg 2 (4)
20 mg 15 (30)
40 mg 31 (62)
Lovastatin
20 mg 1 (50)
80 mg 1 (50)
Table 3 Perioperative patients’ characteristics within first
24 hours
Variable Statin No-Statin p-value
(n = 276) (n = 202)
Laboratory findings
Creatinine serum max. (mg/dl) 1.9 ± 1.25 2.0 ± 3.8 0.58
Increased in serum creatinine (%) 72 ± 116 76 ± 193 0.78
Creatinine clearance min. (ml/min) 57 ± 32 56 ± 31 0.87
Decreased creatinine clearance
(ml/min)
18 ± 34 20 ± 42 0.72
Hematocrit min. (%) 27 ± 4 27 ± 4 0.83
Urea max. (mg/dl) 39 ± 26 42 ± 57 0.44
Furosemide mean (mg/d) 96 ± 158 79 ± 100 0.19
S-CPK (U/L) 973 ± 990 1139 ± 2559 0.37
S-CPK-MB (U/L) 45 ± 45 50 ± 77 0.42
Potassium (mmol/L) 4.5 ± 0.5 4.5 ± 0.5 0.48
Lactate (mmol/L) 1.6 ± 1.4 1.6 ± 1.9 0.64
Renal replacement therapy
during hospital stay (%)
9.1 8.9 0.95
Leucocytes (103/μl) 15 ± 7 14 ± 8 0.0001
Scores
Rifle Score (1st POD)
(n = 285 / 59,6%)
R (risk) n = 60 32 28 0.72
I (injury) n = 65 39 26
F (failure) n = 160 88 72
APACHE II Score 15 ± 6 15 ± 7 0.66
SAPS II Score 25 ± 7 25 ± 8 0.61
Inotropes
Epinephrine (mg/d) 9 ± 123 2 ± 8 0.40
Norepinephrine (mg/d) 2 ± 16 1 ± 6 0.24
Enoximone (mg/d) 20 ± 114 22 ± 195 0.88
Dobutamine (mg/d) 9 ± 44 13 ± 69 0.49
Other agents
Nitroglycerine (mg/d) 12 ± 32 9 ± 21 0.40
Amiodarone (mg/d) 68 ± 286 60 ± 255 0.73
Cortisone (mg/d) 21 ± 119 66 ± 449 0.11
Operative characteristics
Cross-clamp time (min) 94 ± 36 94 ± 41 0.90
Cardiopulmonary bypass time (min) 147 ± 60 140 ± 78 0.30
APACHE Acute Physiology and Chronic Health Evaluation II Score, SAPS:
Simplified Acute Physiology Score, S-CPK Serum creatinine phosphokinase.
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number of patients are shown in Table 2.
Perioperative data
The following data were collected from the patient
in intensive care unit 24 hours after their cardiac sur-
gery operation: laboratory findings (serum creatinine
max., increased in serum creatinie, creatinine clear-
ance min., decrease creatinine clearance, hematocrit
min., serum urea max., furosemide mean, serum cre-
atinine phosphokinase (CPK), serum phosphokinase-
MB (CPK-MB), potassium, lactat acid levels, usage of
renal replacement therapy during hospital stay and
leukocytes). To evaluate the severity of acute illness,
the RIFLE criteria for acute kidney injury (Risk of
renal dysfunction, Injury to the kidney, Failure or Loss
of kidney function, and End-stage kidney disease), the
Acute Physiology and Chronic Health Evaluation II
Score (APACHE II) and the Simplified Acute Physi-
ology Score II (SAPS II) were determined [20-22].
Inotropic support included the need for administra-
tion of epinephrine, norepinephrine, enoximone and
dobutamine. Also the use of nitroglycerin, amiodarone
and cortisone were recorded during the first 24 hours
after the operation.Intraoperative cross-clamp time and cardiopulmonary
bypass times were also recorded and the details are sum-
marized in Table 3.
The extended hemodynamic measurements (Table 4)
included heart rate, absolute arrhythmia, mean arterial
pressure (MAP), central venous pressure (CVP), pulmon-
ary capillary wedge pressure (PCWP), mean pulmonary
Table 4 Hemodynamic parameters
Variable Statin No-Statin p-value
(n = 276) (n = 202)
Hemodynamic
Heart rate (bpm) 82 ± 13 82 ± 12 0.67
MAP (mmHg) 80 ± 8 80 ± 9 0.60
CVP (mmHg) 11 ± 3 11 ± 3 0.205
PCWP (mmHg) 13 ± 5 14 ± 4 0.08
PAP mean (mmHg) 25 ± 5 26 ± 10 0.93
CI (l/min/m2) 2.7 ± 0.5 3.2 ± 3.4 0.30
SVRI (dynsm-²cm-5) 882 ± 206 1050 ± 501 0.022
PVRI (dynsm-²cm-5) 190 ± 121 247 ± 208 0.10
MAP Mean arterial pressure, CVP central venous pressure, PCWP Pulmonary
capillary wedge pressure, PAP Mean pulmonary arterial pressure, CI Cardiac
index, SVRI Systemic Vascular Resistance Index PVRI Pulmonary Vascular
Resistance Index.
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(SVRI) and pulmonary vascular resistance (PVRI).
Postoperative data
To characterize postoperative outcomes of our patients,
we collected the following values: red blood cell trans-
fusion, fresh frozen plasma transfusion, prothrombin
complex concentrates usage (PCC), intra-aortic balloon
pump (IABP), extracorporeal membrane oxygenation
(ECMO), length of ICU stay, hospital stay and in-hospital
death. In-hospital mortality was defined as all-cause
mortality (Table 5).
Statistical analysis
All statistical analyses were performed using Statistica
9.0, StatSoft, Hamburg, Germany. To test for normal dis-
tribution Kolmogorov-Smirnov-Test was used. Ordinal
scaled variables are presented as mean ± standardTable 5 Postoperative outcomes of patients
Variable Statin No-Statin p-value
(n = 276) (n = 202)
Postoperativem outcomes of patients
Red blood cells transfused (ml/d) 250 ± 492 271 ± 750 0.70
Fresh frozen plasma (ml/d) 53 ± 317 113 ± 750 0.23
PCC (U/d) 3.6 ± 60 19.8 ± 204 0.21
IABP (%) 9.8 5 0.05
ECMO (%) 0.4 0 0.50
Onset of atrial fibrillation (%) 18 16 0.51
Length of ICU stay (d) 7 ± 15 7 ± 12 0.99
Hospital stay (d) 25 ± 20 24 ± 21 0.71
Mortality
In-hospital death (n = 38 / 7.9%) (%) 9.1 6.4 0.29
PCC Prothrombin complex concentrates, IABP Intra-aortic balloon pump, ECMO
Extracorporeal membrane oxygenation, ICU Intensive care unit.deviation (SD) and categorical variables are presented as
absolute numbers or percentage. Comparisons of cat-
egorical scaled variables for patients with and without
preoperative statin therapy were made with Fisher’s-
Exact-Test and ordinal variables were compared with
Student’s-T-test. A p value< 0.05 was considered as
statistically significant. A multifactorial analysis was also
performed to detect any statistical difference while
comparing different types and/or doses of statins.
Results
Clinical and demographic data
There was no difference between patients in the statin
group and the no statin group concerning average
age. Both groups had more male than female patients
(p = 0.03). Statin groups had higher rates of Body Mass
Index (p = 0.03), Cigarette Smoking (p = 0.006), Hyper-
tension (p = 0.03) and Diabetes Mellitus (p = 0.001).
There was a higher rate of pulmonary hypertension
in the no statin group (p = 0.02). Other risk factors
and renal function parameters showed no differences
between the two groups. The use of ACE inhibitors
(p = 0.0008), oral nitrates (p = 0.02) and anticoagulation
(p = 0.0001) was higher in the statin group. More
patients of the statin group underwent coronary artery
bypass grafting (p< 0.0001), while the no statin group
had more valve surgery (p< 0.0001) and other proce-
dures (p< 0.0001). The Euroscore revealed no significant
differences between the two groups. All data are sum-
marised in Table 1.
Statin drugs and dosages
In a multivariate analysis, the different types and doses
of statin drugs did not affect the perioperative mortality
in our study groups (Table 2).
Perioperative data
Increased leucocytes were measured in the statin group
(p = 0.0001). The groups did not differ in SAPS II Score,
APACHE II Score and RIFLE Score. The usage of ino-
tropic support achieved no statistical significance (Table 3).
Extended hemodynamic measurements revealed no sig-
nificant difference between the two groups, apart from
SVRI (Systemic Vascular Resistance Index). The no-statin
group had a significantly higher SVRI (882 ± 206 vs. 1050
± 501 dyn*s*cm-5*m-2; p = 0.022). The results of the
hemodynamic parameters are shown in Table 4.
Postoperative data
There was no difference in blood and fresh plasma trans-
fusion, as well as in dose of Prothrombin Complex Con-
centrate (PCC) among the two groups. Also, there was
no statistical difference in length of stay in the intensive
care unit, hospital stay and mortality (Table 5).
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The aim of this study was to check the proclaimed anti-
inflammatory effects of statins on postoperative
hemodynamic parameters. We did not detect a clinical
impact of perioperative statin therapy in patients under-
going cardiac surgery with cardiopulmonary bypass.
The inflammatory response after cardiopulmonary by-
pass is thought to have significant role regarding compli-
cations following cardiopulmonary bypass in cardiac
surgery patients [11,12]. It was shown that the pleio-
tropic effect of statins have a clinical benefit regarding
atrial fibrillation and all-cause mortality [10] due to their
anti-inflammatory effect. The release of pro-inflammatory
cytokines (IL-6, IL-8, and TNF-α) can induce a sys-
temic inflammation which can lead to a change of the
vascular resistance. Statin therapy is being recognized to
have anti-inflammatory effect of injury after cardiopul-
monary bypass; however there are no clinical data which
confirm the influence of statin therapy on perioperative
hemodynamics.
In our study SVRI in the statin group was significantly
lower. The other ascertained hemodynamic parameters
revealed no significant differences between the two
groups. A decrease of SVRI is an evidence for systemic
inflammation, so we could not find an evidence for the
anti-inflammatory effect of statins. Also leucocytes were
increased in both groups, while being higher in the statin
group. We suppose that increased ACE inhibitor treat-
ment in the statin group might have influenced our study
outcome. Boeken et al. pointed out that long-term treat-
ment with ACE inhibitors caused vasodilatatory effects
and enhanced perioperative need for catecholamines.
Furthermore the ACE inhibitor induced vasodilatation
could be one reason for SIRS [23]. So our decreased
SVRI and increased leukocytes probably arose from
long-term ACE inhibitor treatment. This not surprising
because, the majority of cases in the no statin group with
lower cholesterol levels underwent valve surgery. 60.5%
of the patients in the statin group took ACE inhibitors,
because the clinical impact of ACE inhibitor therapy for
patients with coronary heart disease is already approved
[24]. But their use in valve surgery patients is still,
restricted due to their afterload lowering effects.
Further assumed pleiotropic statin effects are preven-
tion of postoperative artrial fibrillation and mortality. In
our study onset of artrial fibrillation was unaffected by
statin therapy. Also mortality was quiet uniform across
all patients. In 2010 Boerger et al. [25] found similar
results in patients undergoing isolated valve surgery.
They failed to detect a protective effect of preoperative
statin therapy on perioperative outcomes or long-term
survival. These results raise the question about the pleio-
tropic effect of statins, the clinical impact of periopera-
tive statin therapy remains unclear.Limitations
Several limitations of this study merit attention. The pri-
mary limitations to this study are its retrospective design
and the analysis of patients from a single institution and
therefore conclusions are necessarily limited in their
application.
It does not seem to be very surprising that the statin
group is dominated by Coronary artery bypass graft
patients, whereas the no-statin group consists of patients
with valvular heart disease with or without coincident
coronary disease. This can have potential influence on
perioperative hemodynamic data. In this retrospective
analysis we did not measure the proclaimed inflamma-
tory effect of on-pump cardiac surgery in terms of
circulating markers of inflammation like IL-6, IL-8, and
TNF-α. However, clinical outcome analysis was focused
on perioperative hemodynamics and we are not able to
provide information on late complications, quality of life,
and cause of death. Moreover, the patient cohort under-
went administration of multiple statin drugs at different
dosages. However, to our knowledge this is the first
study who investigates the perioperative hemodynamic
in terms of statin treatment in a large cohort of cardiac
surgery patients.
Conclusions
The data of this study do not support a benefit in peri-
operative statin therapy for patients undergoing on-pump
cardiac surgery, in terms of postoperative hemodynamic
improvement or clinical outcome.
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